/BCDAW

BCDAW Stock - BioCardia, Inc.

Q: What is the analyst price target for BCDAW?

Analyst price target information is not currently available for BCDAW.

Q: What is BCDAW's market cap?

Market capitalization information is not currently available for BCDAW.

Healthcare|Biotechnology|NASDAQ

$0.01-3.17%

$0.00 (-3.17%) • Aug 2

GoAI Score

Weighted average: Momentum (25%) + Sentiment (35%) + Risk (20%) + Value (20%). ≥70 = BUY, ≤35 = SELL.

HOLD

Medium Confidence

Momentum

Momentum Score

Based on price vs 50-day MA (40%), 200-day MA (40%), and MA crossover (20%). Higher = stronger uptrend.

Sentiment

Sentiment Score

Based on analyst price target upside. 50 = neutral, 100 = very bullish (25%+ upside expected).

Risk Score

Based on stock beta (volatility). Higher score = lower risk. Red (<40) = high volatility, Green (>60) = stable.

Price Target

Average analyst price target from the last quarter. Shows expected upside/downside from current price.

+10.0%upside

Target: $0.01

AI Analysis PreviewPremium

Real-time AI-powered market analysis

Precise entry/exit price targets

Risk assessment & position sizing

Unlock GoAI Insights for BCDAW

Get institutional-grade AI analysis, real-time signals, and deep market intelligence powered by advanced machine learning.

Buy/Sell Signals

94% win rate on Alpha signals

Deep Analysis

Institutional-grade thesis

Real-Time Alerts

SMS & push notifications

Risk Scoring

Multi-factor analysis

Free 14-day trial • No credit card required

Financial Statements

Revenue & Profitability Trend

FY2020

FY2021

FY2022

FY2023

FY2024

← Swipe to see more →

Revenue

Net Income (Profit)

Net Loss

Key Metrics

Market CapN/A

P/E RatioN/A

Beta1.36

52W High$0.01

52W Low$0.01

Avg VolumeN/A

Income Statement (Fiscal Year)

Metric	FY2024	FY2023	FY2022	FY2021	FY2020
Revenue	$58,000	$477,000	$1.35M	$1.01M	$145,000
Gross Profit	$-4,329,000	$-7,249,000	$-7,482,000	$375,000	$141,000
Gross Margin	-7463.8%	-1519.7%	-553.4%	36.9%	97.2%
Operating Income	$-8,000,999	$-11,644,000	$-11,901,000	$-12,630,000	$-15,529,000
Net Income	$-7,946,000	$-11,571,000	$-11,907,000	$-12,621,000	$-15,004,000
Net Margin	-13700.0%	-2425.8%	-880.7%	-1243.4%	-10347.6%
EPS	$-2.90	$-8.19	$-10.05	$-11.19	$-22.20

Company Overview

BioCardia, Inc., a clinical-stage regenerative medicine company, engages in development of cellular and cell-derived therapeutics for cardiovascular and pulmonary diseases. Its lead therapeutic candidate is the CardiAMP, an autologous mononuclear cell therapy system for the treatment of heart failure and chronic myocardial ischemia; and allogeneic cell therapy for cardiac and pulmonary disease. The company is also developing allogeneic cells therapeutic platform, an investigational culture expanded bone marrow derived mesenchymal cell therapy, which is in Phase I/II trial for the treatment of ischemic heart failure. In addition, it offers the Helix biotherapeutic delivery system that delivers therapeutics into the heart muscle with a penetrating helical needle from within the heart; and Morph deflectable guides and sheaths. The company is based in Sunnyvale, California.

Visit Website